Kyowa Kirin Co., Ltd.
4151
株式のランク
#2394
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
株価
$15.74
時価総額
$8.24B
変化（1日）
1.62%
変化（1年）
4.76%
国
JP
取引 Kyowa Kirin Co., Ltd. (4151)
カテゴリー
Healthcare
Kyowa Kirin Co., Ltd.（4151）の収益
Jun 2026 時点の収益 TTM: $3.46B
Kyowa Kirin Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は $3.46B です。2024 年には $3.16B の収益があり、これは 2023 年の $3.14B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Kyowa Kirin Co., Ltd. の収益履歴（2001 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $3.46B | 9.14% |
| 2025 | $3.17B | 0.34% |
| 2024 | $3.16B | 0.66% |
| 2023 | $3.14B | 3.21% |
| 2022 | $3.04B | -0.71% |
| 2021 | $3.06B | -0.76% |
| 2020 | $3.08B | 9.59% |
| 2019 | $2.81B | -10.98% |
| 2018 | $3.16B | 0.78% |
| 2017 | $3.14B | 6.93% |
| 2016 | $2.93B | -3.09% |
| 2015 | $3.03B | 8.70% |
| 2014 | $2.78B | -13.92% |
| 2013 | $3.23B | -16.03% |
| 2012 | $3.85B | -13.50% |
| 2011 | $4.45B | -12.59% |
| 2010 | $5.10B | 53.02% |
| 2009 | $3.33B | -15.32% |
| 2008 | $3.93B | 30.94% |
| 2007 | $3.00B | -0.05% |
| 2006 | $3.00B | -10.40% |
| 2005 | $3.35B | 0.11% |
| 2004 | $3.35B | 10.24% |
| 2003 | $3.04B | 6.34% |
| 2002 | $2.86B | -4.58% |
| 2001 | $2.99B | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $79.67B | 2,204.73% |
US
|
|
| $99.34B | 2,773.76% |
US
|
|
| $64.39B | 1,762.69% |
US
|
|
| $66.40B | 1,820.95% |
US
|
|
| $77.52B | 2,142.61% |
CH
|
